Mitochondrial Iron Chelators for COPD Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) have limited efficacy in inhibiting chronic inflammation and do not reverse the disease pathology, nor do they address the progression of COPD, highlighting a need for new therapies that can prevent the induction and progression of the disease.
Innovation Solution
The use of mitochondrial iron chelators, such as deferiprone, to alleviate mitochondrial dysfunction by regulating iron loading, which is mediated by the Iron Regulating Protein 2 (IRP2), offering a therapeutic approach for COPD and other lung conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for COPD are used, then existing therapy options are maintained, but efficacy in inhibiting chronic inflammation is limited and disease progression is not prevented
Solution Approach 1:
The patent changes the therapeutic parameter from conventional anti-inflammatory approaches to targeting mitochondrial iron homeostasis. By using iron chelators to alter iron metabolism parameters in mitochondria, the treatment achieves both anti-inflammatory effects and disease progression prevention, resolving the contradiction between current treatment reliability and productivity.
Solution Approach 2:
The patent introduces mitochondrial iron chelators as an intermediary substance that mediates between iron metabolism and inflammation. These chelators bind excess mitochondrial iron, preventing iron-induced oxidative stress and inflammation, thereby improving both anti-inflammatory efficacy and disease prevention capabilities simultaneously.
2Stability of the object's composition
If current COPD treatments are used, then existing therapeutic approaches are maintained, but they do not reverse disease pathology or modify factors driving long-term progression
Solution Approach 1:
The patent applies preliminary action by targeting the underlying mitochondrial iron dysregulation that drives disease pathology. By correcting iron homeostasis early in the disease process, the treatment can prevent pathological changes before they become irreversible, enabling reversal of early pathology and modification of disease-driving factors.
Solution Approach 2:
The patent converts the harmful effect of excess mitochondrial iron (which drives inflammation and pathology) into a benefit by using iron chelators to selectively remove the excess iron. This transforms the iron overload problem into a therapeutic opportunity, allowing reversal of iron-induced pathology while maintaining necessary iron functions.
3Reliability
If mitochondrial iron chelators are used, then mitochondrial dysfunction is alleviated and inflammation is reduced, but new therapeutic mechanism complexity is introduced
Solution Approach 1:
The patent extracts the specific pathological element (excess mitochondrial iron) from the complex cellular environment. By using selective iron chelators that target only mitochondrial iron pools, the treatment simplifies the therapeutic approach to a single targeted mechanism while achieving complex anti-inflammatory and disease-modifying effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Mitochondrial iron chelation effectively reduces inflammation and mitochondrial dysfunction, providing a potential therapeutic strategy to prevent and treat COPD by targeting the pathogenic mechanisms driven by IRP2 in COPD susceptibility.
Implementation Method 1
mitochondrial iron chelators, such as deferiprone, to alleviate mitochondrial dysfunction by regulating iron loading
Data Source
Figure 1a~1b
Figure 1c~1d
Figure 1e
AI summary
A method for treating one or more symptoms of COPD comprising administering to an in need of treatment a therapeutically effect amount of one or more mitochondrial iron chelators. The mitochondrial iron chelator can be deferiprone. Compositions comprising mitochondrial iron chelators suitable for administration are also disclosed.